• Je něco špatně v tomto záznamu ?

Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450

J. Nekvindova, A. Mrkvicova, V. Zubanova, A. Hyrslova Vaculova, P. Anzenbacher, P. Soucek, L. Radova, O. Slaby, I. Kiss, J. Vondracek, A. Spicakova, L. Bohovicova, P. Fabian, Z. Kala, V. Palicka,

. 2020 ; 177 (-) : 113912. [pub] 20200313

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028039

Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028039
003      
CZ-PrNML
005      
20211227134725.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2020.113912 $2 doi
035    __
$a (PubMed)32173367
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nekvindova, Jana $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic. Electronic address: nekvindova@fnhk.cz.
245    10
$a Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450 / $c J. Nekvindova, A. Mrkvicova, V. Zubanova, A. Hyrslova Vaculova, P. Anzenbacher, P. Soucek, L. Radova, O. Slaby, I. Kiss, J. Vondracek, A. Spicakova, L. Bohovicova, P. Fabian, Z. Kala, V. Palicka,
520    9_
$a Hepatocellular carcinoma (HCC) remains a highly prevalent and deadly disease, being among the top causes of cancer-related deaths worldwide. Despite the fact that the liver is the major site of biotransformation, studies on drug metabolizing enzymes in HCC are scarce. It is known that malignant transformation of hepatocytes leads to a significant alteration of their metabolic functions and overall deregulation of gene expression. Advanced stages of the disease are thus frequently associated with liver failure, and severe alteration of drug metabolism. However, the impact of dysregulation of metabolic enzymes on therapeutic efficacy and toxicity in HCC patients is largely unknown. Here we demonstrate a significant down-regulation in European Caucasian patients of cytochromes P450 (CYPs), the major xenobiotic-metabolizing enzymes, in HCC tumour samples as compared to their surrounding non-cancerous (reference) tissue. Moreover, we report for the first time the association of the unique CYP profiles with specific transcriptome changes, and interesting correlations with expression levels of nuclear receptors and with the histological grade of the tumours. Integrated analysis has suggested certain co-expression profiles of CYPs with lncRNAs that need to be further characterized. Patients with large tumours with down-regulated CYPs could be more vulnerable to drug toxicity; on the other hand, such tumours would eliminate drugs more slowly and should be more sensitive to pharmacotherapy (except in the case of pro-drugs where activation is necessary).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a hepatocelulární karcinom $x enzymologie $x patologie $7 D006528
650    _2
$a kohortové studie $7 D015331
650    _2
$a systém (enzymů) cytochromů P-450 $x genetika $7 D003577
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese enzymů $7 D015971
650    _2
$a hepatocyty $x metabolismus $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a metabolická inaktivace $x genetika $7 D008658
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a nádory jater $x enzymologie $x patologie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a receptory cytoplazmatické a nukleární $x genetika $x metabolismus $7 D018160
650    12
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mrkvicová, Alena $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic; Department of Medical Biochemistry, Charles University, Faculty of Medicine in Hradec Kralove, Czech Republic. Electronic address: MrkvicovaA@lfhk.cuni.cz. $7 xx0267751
700    1_
$a Zubanova, Veronika $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic. Electronic address: veronikazubanova@gmail.com.
700    1_
$a Hyrslova Vaculova, Alena $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Electronic address: vaculova@ibp.cz.
700    1_
$a Anzenbacher, Pavel $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: pavel.anzenbacher@upol.cz.
700    1_
$a Soucek, Pavel $u Center for Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address: pavel.soucek@szu.cz.
700    1_
$a Radova, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Electronic address: lenka.radova@ceitec.muni.cz.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. Electronic address: on.slaby@gmail.com.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic. Electronic address: kiss@mou.cz.
700    1_
$a Vondracek, Jan $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic. Electronic address: vondracek@ibp.cz.
700    1_
$a Spicakova, Alena $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: alonek@centrum.cz.
700    1_
$a Bohovicova, Lucia $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic. Electronic address: bohovicova@mou.cz.
700    1_
$a Fabian, Pavel $u Department of Oncological and Experimental Pathology, Cancer Institute, Brno, Czech Republic. Electronic address: fabian@mou.cz.
700    1_
$a Kala, Zdenek $u Department of Surgery, University Hospital Brno, Czech Republic. Electronic address: Kala.Zdenek@fnbrno.cz.
700    1_
$a Palicka, Vladimir $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic. Electronic address: palicka@lfhk.cuni.cz.
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 177, č. - (2020), s. 113912
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32173367 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20211227134724 $b ABA008
999    __
$a ok $b bmc $g 1608374 $s 1119219
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 177 $c - $d 113912 $e 20200313 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace